George Lipkin at [NYU Langone Health]

George Lipkin, MD

  • Specialty: Dermatology
  • Languages: English, French, Spanish
  • Phone: 212-689-4884
View Locations

About Me

Conditions and Treatments

acne rosacea, vitiligo, psoriasis, wart, nail disease


  • Professor, Ronald O. Perelman Department of Dermatology
Board Certifications
  • American Board of Dermatology - Dermatology, 1961
Education and Training
  • Residency, NYU Medical Center, Dermatolgy, 1961
  • Residency, NYU Medical Center, Dermatology, 1957

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Locations and Appointments

17 Insurance Plans Accepted
  • Aetna HMO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Empire NYS Plan
  • HIP Child Health
  • Medicare
  • Oxford Freedom
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
George Lipkin, M.D.

530 1st Avenue, Suite 7C
New York, NY 10016

Research My Research


reversing malignant melanoma-restoring host control

Research Summary

Current treatment of malignancy is hindered by tumor cell heterogeneity and progressive clonal evolution. Reversion of the malignant phenotype by differentiation agents could favorably alter the tumor/host relationship by stabilizing phenotypes and reducing heterogeneity. We have identified a unique endogenous inhibitor in a revertant melanoma line, which restores normal growth control--density-, anchorage-, and serum-dependence--to melanoma cells. It induces early Gl growth arrest, differentiation antigens, and decreased susceptibility to natural killer cells with increased vulnerability to cytotoxic T cells and with increased class I MHC expression. Effects are nontoxic, reversible, and transcend species and tissue barriers. Treated melanoma and hepatoma cells exhibited striking cytoskeletal reorganization, including changes in an actin-binding substrate for phosphorylation by the EGF receptor. In situ treatment of lethal hamster melanoma transplants with liposome-entrapped partially purified inhibitor for 30 days led to complete tumor regression and 100% survival. In situ administration of inhibitor in an aqueous suspension to C57BL/6J mice with established subcutaneous Lewis lung carcinomas led to regression of 75% of tumors (no survivors in control mice). This new inhibitor appears to favorably alter the biologic balance between tumor and host by reducing heterogeneity, restoring sensitivity to normal environmental signals governing growth, and inducing surface markers which alert and facilitate host response. We have partially purified this inhibitor and distinguished it from other known tumor inhibitors. Our laboratory's focus is on completing purification, well under way, and developing a new, powerful, nontoxic, biologically rational, and more effective therapy for currently incurable cancers.

Academic Contact

Academic office

530 First Avenue

Suite 7C

New York, NY 10016



Research Interests Timeline

These focus areas and their associated publications are derived from PubMed and the MeSH term library.
represents one publication


Read All Publications (56)